On January 20, the United States Congress released the FY2026 Labor, Health and Human Services, Education, and Related Agencies appropriations bill, reaffirming bipartisan support for advancing cancer research and saving lives through sustained and increased funding for the National Institutes of Health and the National Cancer Institute.
Critical cancer prevention efforts also received support, including funding for the National Breast and Cervical Cancer Early Detection Program and maintenance of tobacco control initiatives. These investments help ensure that more people have access to screenings that can catch cancer early, when it’s most treatable.
A notable policy victory included in the bill is language based on the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection (MCED) Screening Coverage Act. This provision would allow Medicare to cover certain multi-cancer detection tests once they are approved by the FDA and shown to provide clinical benefit, potentially expanding access to cutting-edge, blood-based screening technology for older adults.
Lawmakers from both parties emphasized that cancer research and prevention remain national priorities. Advocates and policy leaders applauded the commitment to funding that supports scientific innovation, improves access to care, and accelerates progress toward better patient outcomes.
What This Means for Progress
This appropriations package positions the cancer research community to continue making strides in understanding and combating the disease, from fundamental research at NIH and NCI to real-world impacts like expanded screening coverage and sustained prevention programs. As funding translates into action, patients and families stand to benefit from more discoveries, earlier detection, and improved treatments in the years ahead.
